• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Elan CEO says $1 billion royalty deal with Theravance a unique opportunity

Elan CEO says $1 billion royalty deal with Theravance a unique opportunity

May 14, 2013
CenterWatch Staff

Elan has announced a royalty agreement with Theravance, by which Elan will make a one-time cash payment of $1 billion to Theravance in exchange for a 21% participation interest in the potential future royalty payments from four respiratory programs for which Theravance has partnered with GlaxoSmithKline, when and if received by Theravance.

“The transaction announced today is a truly unique opportunity,” said Kelly Martin, Elan CEO. “This investment enables our shareholders to gain exposure to four high-quality, late-stage assets within the large and growing global respiratory market. The commercial and marketing execution for these assets will be driven by GSK, the dominant global leader in this therapeutic area with a current market share of more than 40%.”

“The opportunity to diversify our business across a number of dimensions, grow the P&L and offer our shareholders participation in additional high-margin assets with the potential for extremely long-term cash flow is attractive for the short, intermediate and long term,” he said. “These four respiratory assets combined with Tysabri—currently approved for Relapsing Remitting Multiple Sclerosis—as well as their aggregated potential cash flow, provides a one-of-a-kind financial platform and investment thesis for public equity investors globally.”

“The Theravance transaction is an important next step in the implementation of our strategy,” he added. “It is, however, only one piece of the equation and, to that end, we intend to make further announcements regarding other assets and specific opportunities in the near future. All of our strategic activity has been, and will continue to be, consistent with our guiding principles of achieving balance from an investment, risk and return, and timeline perspective.”

Elan will initiate a cash dividend policy enabling its shareholders to benefit directly from the long-term cash flow expected to be generated by the four respiratory products under the agreement with Theravance. The percentage to be paid out directly to shareholders will be 20% of the amounts paid to Elan, and the company expects to pay these cash dividends in twice-yearly installments.

“We are very excited to partner with Elan in a transaction that recognizes the significant value of four programs from our GSK collaborations targeted at respiratory disease,” said Rick E. Winningham, CEO of Theravance. “This agreement complements our strategy to facilitate and accelerate the return of capital to our stockholders and build value, consistent with our recently announced plan to separate Theravance into two entities, Royalty Management Company and Theravance Biopharma.”

The four GSk programs are: RELVAR ELLIPTA/BREO ELLIPTA, ANORO ELLIPTA, MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist) monotherapy (GSK961081, or MABA ‘081), and vilanterol (VI) monotherapy.  For RELVAR ELLIPTA/BREO ELLIPTA and VI, Theravance is entitled to receive 15% of the first $3 billion of combined annual global net sales, and 5% of combined annual global net sales above $3 billion. If ANORO ELLIPTA is approved and commercialized, royalties on annual global net sales are tiered and range from the mid-single digits to 10%. MABA ‘081 is an investigational medicine in development under the strategic alliance between Theravance and GSK. If MABA ‘081 is successfully developed and commercialized as a monotherapy, Theravance is entitled to receive royalties of 10% to 20% of the first $3.5 billion of annual global net sales, and 7.5% of all annual global net sales above $3.5 billion.

The transaction is not subject to any material conditions, other than approval by Elan’s shareholders. If approved, the transaction should be complete by the end of June.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing